Advertisement
Journal Home
Search for

Volume 9, Issue 8, Pages 818-822 (December 2008)


View previous. 5 of 29 View next.

Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam

Ingebjørg GustavsenaCorresponding Author Informationemail address, Jørgen G. Bramnessb, Svetlana Skurtveitbc, Anders Engelandbd, Ineke Neutele, Jørg Mørlandaf

Received 24 September 2007; received in revised form 12 November 2007; accepted 13 November 2007.

Abstract 

Background

Despite the high prescription rate of benzodiazepine-like hypnotics (z-hypnotics), there is limited information on the road traffic accident risk associated with the use of these drugs. We wanted to investigate whether filling a prescription for zopiclone or zolpidem was associated with increased risk of road traffic accidents at a national population level. Nitrazepam and flunitrazepam were used as comparator drugs.

Method

All Norwegians 18–69 years (3.1 million) were followed-up from January 2004 until the end of September 2006. Information on prescriptions, road traffic accidents and emigration/death was obtained from three Norwegian population-based registries. The first week after the hypnotics had been dispensed was considered to be the exposure period. Standardized incidence ratios (SIRs) were calculated by comparing the incidence of accidents in the exposed person-time to the incidence of accidents in the unexposed person-time.

Results

During exposure, 129 accidents were registered for zopiclone, 21 for zolpidem, 27 for nitrazepam and 18 for flunitrazepam. The SIRs were (SIR for all ages and both sexes combined; 95% CI): z-hypnotics (zopiclone+zolpidem) 2.3; 2.0–2.7, nitrazepam 2.7; 1.8–3.9 and flunitrazepam 4.0; 2.4–6.4. The highest SIRs were found among the youngest users for all hypnotics.

Conclusions

This study found that users of hypnotics had a clearly increased risk of road traffic accidents. The SIR for flunitrazepam was particularly high.

a Division of Forensic Toxicology and Drug Abuse, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, NO-0403 Oslo, Norway

b Department of Pharmacoepidemiology, Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway

c Department of Pharmacy, University of Tromsø, Norway

d Department of Public Health and Primary Health Care, Section of Epidemiology and Medical Statistics, University of Bergen, Bergen, Norway

e Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Canada

f Institute of Pharmacology, University of Oslo, Oslo, Norway

Corresponding Author InformationCorresponding author. Tel.: +47 23 40 78 00; fax: +47 23 40 78 78.

PII: S1389-9457(07)00424-8

doi:10.1016/j.sleep.2007.11.011


View previous. 5 of 29 View next.

Advertisement